Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €31.11 EUR
Change Today +1.15 / 3.82%
Volume 0.0
MYD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:18 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for myriad genetics inc (MYD)

Myriad Genetics Inc. uses little or no debt in its capital structure and may have less financial risk than the industry aggregate. Accounts Receivable are among the industry's worst with 41.19 days worth of sales outstanding. This implies that revenues are not being collected in an efficient manner. Last, Myriad Genetics Inc. is among the least efficient in its industry at managing inventories, with 48.53 days of its Cost of Goods Sold tied up in Inventories.
Currency in
Millions of US Dollars
As of:Jun 30
2011
Restated
Jun 30
2012
Restated
Jun 30
2013
Jun 30
2014
4 Year
Trend
Assets    
Cash and Equivalents52.786.4104.164.8
Short-Term Investments293.8254.2268.2121.6
TOTAL CASH AND SHORT TERM INVESTMENTS346.5340.5372.3186.5
Accounts Receivable50.360.494.381.3
Other Receivables0.62.72.63.8
TOTAL RECEIVABLES50.863.197.085.1
Inventory8.211.65.023.9
Prepaid Expenses2.91.71.720.5
Deferred Tax Assets, Current9.85.68.06.4
TOTAL CURRENT ASSETS418.3422.5484.0322.4
Gross Property Plant and Equipment64.172.584.299.6
Accumulated Depreciation-41.0-48.3-56.6-65.0
NET PROPERTY PLANT AND EQUIPMENT23.124.227.634.6
Goodwill56.156.956.9169.2
Long-Term Investments70.9113.7158.784.1
Loans Receivable, Long Term--19.021.7--
Deferred Tax Assets, Long Term25.930.628.63.2
Other Intangibles16.715.713.3205.3
Other Long-Term Assets--8.013.05.0
TOTAL ASSETS610.8690.6803.8823.8
    
LIABILITIES & EQUITY    
Accounts Payable11.410.118.123.1
Accrued Expenses21.632.844.356.4
Unearned Revenue, Current1.32.12.01.1
TOTAL CURRENT LIABILITIES34.445.064.580.6
Other Non-Current Liabilities9.610.010.724.2
TOTAL LIABILITIES44.055.075.2104.8
Common Stock0.90.80.80.7
Additional Paid in Capital604.4647.7697.3717.8
Retained Earnings-38.6-12.730.92.0
Comprehensive Income and Other0.2-0.2-0.4-1.5
TOTAL COMMON EQUITY566.8635.7728.6719.0
TOTAL EQUITY566.8635.7728.6719.0
TOTAL LIABILITIES AND EQUITY610.8690.6803.8823.8
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYD:GR €31.11 EUR +1.15

MYD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $29.28 USD -0.05
Alliance HealthCare Services Inc $18.33 USD -0.36
Bio-Reference Laboratories Inc $41.26 USD +0.01
Genomic Health Inc $27.34 USD -0.45
RadNet Inc $6.69 USD 0.00
View Industry Companies
 

Industry Analysis

MYD

Industry Average

Valuation MYD Industry Range
Price/Earnings 27.1x
Price/Sales 3.3x
Price/Book 3.6x
Price/Cash Flow 24.8x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.